Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1
Cyclin-dependent protein kinases (CDKs) are important regulators of cellular processes and are functionally integrated into the replication of human cytomegalovirus (HCMV). Recently, a regulatory impact of CDK activity on the viral mRNA export factor pUL69 was shown. Here, specific aspects of the mode of interaction between CDK9/cyclin T1 and pUL69 are described. Intracellular localization was studied in the presence of a novel selective CDK9 inhibitor, R22, which exerts anti-cytomegaloviral activity in vitro. A pronounced R22-induced formation of nuclear speckled aggregation of pUL69 was demonstrated. Multi-labelling confocal laser-scanning microscopy revealed that CDK9 and cyclin T1 co-localized perfectly with pUL69 in individual speckles. The effects were similar to those described recently for the broad CDK inhibitor roscovitine. Co-immunoprecipitation and yeast two-hybrid analyses showed that cyclin T1 interacted with both CDK9 and pUL69. The interaction region of pUL69 for cyclin T1 could be attributed to aa 269–487. Moreover, another component of CDK inhibitor-induced speckled aggregates was identified with RNA polymerase II, supporting earlier reports that strongly suggested an association of pUL69 with transcription complexes. Interestingly, when using a UL69-deleted recombinant HCMV, no speckled aggregates were formed by CDK inhibitor treatment. This indicated that pUL69 is the defining component of aggregates and generally may represent a crucial viral interactor of cyclin T1. In conclusion, these data emphasize that HCMV inter-regulation with CDK9/cyclin T1 is at least partly based on a pUL69–cylin T1 interaction, thus contributing to the importance of CDK9 for HCMV replication.
BiglioneS.,
ByersS. A.,
PriceJ. P.,
NguyenV. T.,
BensaudeO.,
PriceD. H.,
MauryW.2007; Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 4:47 [View Article][PubMed]
BorstE. M.,
HahnG.,
KoszinowskiU. H.,
MesserleM.1999; Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73:8320–8329[PubMed]
BresnahanW. A.,
BoldoghI.,
ChiP.,
ThompsonE. A.,
AlbrechtT.1997; Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 231:239–247 [View Article][PubMed]
ChanG.,
NogalskiM. T.,
YurochkoA. D.2009; Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. Proc Natl Acad Sci U S A 106:22369–22374 [View Article][PubMed]
ChengY.-C.,
PrusoffW. H.1973; Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108 [View Article][PubMed]
Dai-JuJ. Q.,
LiL.,
JohnsonL. A.,
Sandri-GoldinR. M.2006; ICP27 interacts with the C-terminal domain of RNA polymerase II and facilitates its recruitment to herpes simplex virus 1 transcription sites, where it undergoes proteasomal degradation during infection. J Virol 80:3567–3581 [View Article][PubMed]
DatsenkoK. A.,
WannerB. L.2000; One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640–6645 [View Article][PubMed]
De AzevedoW. F.,
LeclercS.,
MeijerL.,
HavlicekL.,
StrnadM.,
KimS.-H.1997; Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243:518–526 [View Article][PubMed]
de la FuenteC.,
MaddukuriA.,
KehnK.,
BaylorS. Y.,
DengL.,
PumferyA.,
KashanchiF.2003; Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. Curr HIV Res 1:131–152 [View Article][PubMed]
DurfeeT.,
BechererK.,
ChenP. L.,
YehS. H.,
YangY.,
KilburnA. E.,
LeeW. H.,
ElledgeS. J.1993; The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Genes Dev 7:555–569 [View Article][PubMed]
FischerP. M.,
Gianella-BorradoriA.2003; CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 12:955–970 [View Article][PubMed]
FortunatoE. A.,
McElroyA. K.,
SanchezI.,
SpectorD. H.2000; Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus. Trends Microbiol 8:111–119 [View Article][PubMed]
HayashiM. L.,
BlankenshipC.,
ShenkT.2000; Human cytomegalovirus UL69 protein is required for efficient accumulation of infected cells in the G1 phase of the cell cycle. Proc Natl Acad Sci U S A 97:2692–2696 [View Article][PubMed]
HergetT.,
MarschallM.2006; Recent developments in anti-herpesviral combination therapy based on protein kinase inhibitors. In New Concepts of Antiviral Therapy pp. 351–371 Edited by
HolzenburgA.,
BognerE.
London: Springer; [View Article]
HergetT.,
FreitagM.,
MorbitzerM.,
KupferR.,
StammingerT.,
MarschallM.2004; Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob Agents Chemother 48:4154–4162 [View Article][PubMed]
HofmannH.,
FlössS.,
StammingerT.2000; Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b. J Virol 74:2510–2524 [View Article][PubMed]
IsaacsonM. K.,
FeireA. L.,
ComptonT.2007; Epidermal growth factor receptor is not required for human cytomegalovirus entry or signaling. J Virol 81:6241–6247 [View Article][PubMed]
JaultF. M.,
JaultJ. M.,
RuchtiF.,
FortunatoE. A.,
ClarkC.,
CorbeilJ.,
RichmanD. D.,
SpectorD. H.1995; Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol 69:6697–6704[PubMed]
KapasiA. J.,
SpectorD. H.2008; Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. J Virol 82:394–407 [View Article][PubMed]
KapasiA. J.,
ClarkC. L.,
TranK.,
SpectorD. H.2009; Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription. J Virol 83:5904–5917 [View Article][PubMed]
KudohA.,
FujitaM.,
KiyonoT.,
KuzushimaK.,
SugayaY.,
IzutaS.,
NishiyamaY.,
TsurumiT.2003; Reactivation of lytic replication from B cells latently infected with Epstein–Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication. J Virol 77:851–861 [View Article][PubMed]
LeV. T.,
TrillingM.,
WilbornM.,
HengelH.,
ZimmermannA.2008; Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J Gen Virol 89:2416–2426 [View Article][PubMed]
LischkaP.,
RosoriusO.,
TrommerE.,
StammingerT.2001; A novel transferable nuclear export signal mediates CRM1-independent nucleocytoplasmic shuttling of the human cytomegalovirus transactivator protein pUL69. EMBO J 20:7271–7283 [View Article][PubMed]
LischkaP.,
TothZ.,
ThomasM.,
MuellerR.,
StammingerT.2006; The UL69 transactivator protein of human cytomegalovirus interacts with DEXD/H-Box RNA helicase UAP56 to promote cytoplasmic accumulation of unspliced RNA. Mol Cell Biol 26:1631–1643 [View Article][PubMed]
MajelloB.,
NapolitanoG.2001; Control of RNA polymerase II activity by dedicated CTD kinases and phosphatases. Front Biosci 6:D1358–D1368 [View Article][PubMed]
MarschallM.,
FreitagM.,
WeilerS.,
SorgG.,
StammingerT.2000; Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob Agents Chemother 44:1588–1597 [View Article][PubMed]
MettH.,
HölscherK.,
DegenH.,
EsdarC.,
De NeumannB. F.,
FlickeB.,
FreudenreichT.,
HolzerG.,
SchinzelS. et al.2005; Identification of inhibitors for a virally encoded protein kinase by 2 different screening systems: in vitro kinase assay and in-cell activity assay. J Biomol Screen 10:36–45 [View Article][PubMed]
MocarskiE. S.Jr,
ShenkT.,
PassR. F.2007; Cytomegalovirus. In Fields Virology, 5th edn. pp. 2701–2772 Edited by
KnipeM.,
HowleyP. M.
Philadelphia, PA: Lippincott Williams & Wilkins;
NapolitanoG.,
LicciardoP.,
CarboneR.,
MajelloB.,
LaniaL.2002; CDK9 has the intrinsic property to shuttle between nucleus and cytoplasm, and enhanced expression of cyclin T1 promotes its nuclear localization. J Cell Physiol 192:209–215 [View Article][PubMed]
PumferyA.,
de la FuenteC.,
BerroR.,
NekhaiS.,
KashanchiF.,
ChaoS. H.2006; Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr Pharm Des 12:1949–1961 [View Article][PubMed]
RechterS.,
ScottG. M.,
EickhoffJ.,
ZielkeK.,
AuerochsS.,
MüllerR.,
StammingerT.,
RawlinsonW. D.,
MarschallM.2009; Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity. J Biol Chem 284:8605–8613 [View Article][PubMed]
SalvantB. S.,
FortunatoE. A.,
SpectorD. H.1998; Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription. J Virol 72:3729–3741[PubMed]
SanchezV.,
SpectorD. H.2006; Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles. J Virol 80:5886–5896 [View Article][PubMed]
SanchezV.,
McElroyA. K.,
SpectorD. H.2003; Mechanisms governing maintenance of Cdk1/cyclin B1 kinase activity in cells infected with human cytomegalovirus. J Virol 77:13214–13224 [View Article][PubMed]
SanchezV.,
McElroyA. K.,
YenJ.,
TamrakarS.,
ClarkC. L.,
SchwartzR. A.,
SpectorD. H.2004; Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122–123 and UL37 immediate-early transcripts and at later times for virus production. J Virol 78:11219–11232 [View Article][PubMed]
SchangL. M.2005b; Discovery of the antiviral activities of pharmacologic cyclin-dependent kinase inhibitors: from basic to applied science. Expert Rev Anti Infect Ther 3:145–149 [View Article][PubMed]
SchangL. M.,
St VincentM. R.,
LacasseJ. J.2006; Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir Chem Chemother 17:293–320[PubMed][CrossRef]
SchregelV.,
AuerochsS.,
JochmannR.,
MaurerK.,
StammingerT.,
MarschallM.2007; Mapping of a self-interaction domain of the cytomegalovirus protein kinase pUL97. J Gen Virol 88:395–404 [View Article][PubMed]
ScottG. M.,
WeinbergA.,
RawlinsonW. D.,
ChouS.2007; Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 51:89–94 [View Article][PubMed]
SportsmanJ. R.,
GaudetE. A.,
BogeA.2004; Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening. Assay Drug Dev Technol 2:205–214 [View Article][PubMed]
TamrakarS.,
KapasiA. J.,
SpectorD. H.2005; Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7. J Virol 79:15477–15493 [View Article][PubMed]
TavalaiN.,
KraigerM.,
KaiserN.,
StammingerT.2008; Insertion of an EYFP-pp71 (UL82) coding sequence into the human cytomegalovirus genome results in a recombinant virus with enhanced viral growth. J Virol 82:10543–10555 [View Article][PubMed]
ThomasM.,
RechterS.,
MilbradtJ.,
AuerochsS.,
MüllerR.,
StammingerT.,
MarschallM.2009; Cytomegaloviral protein kinase pUL97 interacts with the nuclear mRNA export factor pUL69 to modulate its intranuclear localization and activity. J Gen Virol 90:567–578 [View Article][PubMed]
TothZ.,
LischkaP.,
StammingerT.2006; RNA-binding of the human cytomegalovirus transactivator protein UL69, mediated by arginine-rich motifs, is not required for nuclear export of unspliced RNA. Nucleic Acids Res 34:1237–1249 [View Article][PubMed]
WangD.,
de la FuenteC.,
DengL.,
WangL.,
ZilbermanI.,
EadieC.,
HealeyM.,
SteinD.,
DennyT. et al.2001; Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 75:7266–7279 [View Article][PubMed]
WinklerM.,
StammingerT.1996; A specific subform of the human cytomegalovirus transactivator protein pUL69 is contained within the tegument of virus particles. J Virol 70:8984–8987[PubMed]
WinklerM.,
RiceS. A.,
StammingerT.1994; UL69 of human cytomegalovirus, an open reading frame with homology to ICP27 of herpes simplex virus, encodes a transactivator of gene expression. J Virol 68:3943–3954[PubMed]
Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1